Live flu vaccine trial

By Kate McDonald
Friday, 27 February, 2009

Melbourne’s BioDiem and Schering-Plough’s vaccine business unit Nobilon have begun a clinical development program for BioDiem’s intranasal live attenuated influenza vaccine (LAIV).

The vaccine, named SCH 900795, is composed of three attenuated flu viruses that will be delivered in a single-dose intranasal spray.

The Phase I study will test the safety, tolerability and immunogenicity of the vaccine in 120 healthy volunteers.

Scientists uncover how cancer cells hide from immune system

By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Content from other channels on our network

Container Exchange appoints new CEO

Floating wetland pods cut greenhouse gas emissions

Wind turbines won't solve Vic's energy grid woes

Consistent weaknesses found in corporate net zero claims

How digital textile printing can rebuild local manufacturing in Australia

Medicare Mental Health Check In — helping clinicians close the gap

Health professionals FAQ for Medicare Mental Health Check In

Top 4 lessons from an ICAC NSW Health employee investigation

[On-Demand Webinar] Transform from Security Awareness to a Security Culture: A Vital Shift for SMB Healthcare

[On-Demand Webinar] When Connectivity Becomes Critical Care: Building more connected healthcare and aged care facilities

Dual conveying systems automate chocolate cream production

Packaging refresh for Victorian craft spirits brand

Aussie lolly brand to expand into the US market

Massey University expands its youth program across food and fibre sector

NZ's winemaker and viticulturist awards announced